The aim of the LOVE-DEB Study (Large de-NOVo coronary artEry disease treated with sirolimus Drug Eluting Balloon: prospective evaluation of safety & ef...
“We are building a new ecosystem in global public health,” said Anuradha Gupta, President of Global Immunization at Sabin. “We aim to cre...
ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is pleased to ...
As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the prelimina...
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age a...
Depression affects nearly 300 million individuals worldwide and does not have a universally effective treatment. The US economic burden as a result of depr...
Insomnia is a sleep disorder with difficulty falling asleep or staying asleep, early awakening and so on. It is also the most common complaints in primary ...
To help protect access to medicines for cancer and rare disease patients, AstraZeneca has filed a legal challenge to critical aspects of the drug pri...
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) f...
The HD-MAP platform technology offers user-friendly vaccines, allowing possible self-administration. Its room temperature stability revolutionizes distri...
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), announced that its IoNovo Iodine product has been gr...
One in Four American Adults Would Rather Not Know They Have Cancer A new study from The Harris Poll, commissioned by Bayer, suggests fear factors ...
Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences. Now with its own permanent ...
TARPEYO is currently approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progr...
© 2024 Biopharma Boardroom. All Rights Reserved.
